ArticleWorld journal of gastroenterology2013
Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation.
Article in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Clinical Value of Inflammatory Indexes in Predicting Post-Transplantation Prognosis in Hepatocellular Carcinoma: A Retrospective Cohort Study.Journal of inflammation research · 2026Article
- Roles of cytokine storm in sepsis progression: biomarkers, and emerging therapeutic strategies.Frontiers in immunology · 2025Review
- Performance of the neutrophil-to-lymphocyte ratio as a prognostic tool for survival in solid cancers.Frontiers in oncology · 2025Article
- Article
- Living donor liver transplantation for Barcelona clinic liver cancer (BCLC) intermediate-stage hepatocellular carcinoma.Hepatobiliary surgery and nutrition · 2023Article
- Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis.Journal of cancer research and clinical oncology · 2023Article
- Tailored Prediction Model of Survival after Liver Transplantation for Hepatocellular Carcinoma.Journal of clinical medicine · 2021Article
- Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer.Scientific reports · 2019Article
- Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation.World journal of hepatology · 2019Review
- Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria.Journal of hepatocellular carcinoma · 2019Review
- C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation.PloS one · 2019Article
- Diagnostic value of alpha-fetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma.BMC gastroenterology · 2018Article
- Systemic immune-inflammation index in germ-cell tumours.British journal of cancer · 2018Article
- Article
- Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma.Journal of hepatocellular carcinoma · 2018Review
- Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib.Oncotarget · 2017Article
- Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib.Molecular and clinical oncology · 2017Article
- Observational
- Neutrophil-lymphocyte Ratio Plus Prognostic Nutritional Index Predicts the Outcomes of Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization.Scientific reports · 2017Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine whether an elevated neutrophil-lymphocyte ratio (NLR) is negatively associated with tumor recurrence in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after liver transplantation (LT), and to determine the optimal predictive NLR cut-off value.
methodsThe data of HCC patients who had undergone LT came from the China Liver Transplant Registry database. We collected data from 326 liver cancer patients who had undergone LT at our medical center. We divided the patients into groups based on their NLRs (3, 4 or 5). We then compared the clinicopathological data and long-time survival between these groups. Meanwhile, we used receiver operating characteristic analysis to determine the optimal NLR cut-off.
resultsOf 280 HCC patients included in this study, 263 were HBV positive. Patients with an NLR < 3 and patients with an NLR ≥ 3 but < 4 showed no significant differences in overall survival (OS) (P = 0.212) or disease-free survival (DFS) (P = 0.601). Patients with an NLR ≥ 4 but < 5 and patients with an NLR ≥ 5 also showed no significant differences in OS (P = 0.208) or DFS (P = 0.618). The 1-, 3- and 5-year OS rates of patients with an NLR < 4 vs an NLR ≥ 4 were 87.8%, 63.8% and 61.5% vs 73.9%, 36.7% and 30.3%, respectively (P < 0.001). The 1-, 3- and 5-year DFS rates of patients with an NLR < 4 vs NLR ≥ 4 were 83.9%, 62.9% and 60.7% vs 64.9%, 30.1% and 30.1%, respectively (P < 0.001). Univariate and multivariate analyses demonstrated that three factors, including NLR ≥ 4 (P = 0.002), were significant predictors of tumor recurrence in HCC patients after LT.
conclusionA preoperative elevated NLR significantly increased the risk for tumor recurrence in HCC patients after LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.